We have previously demonstrated that an immunotherapeutic approach that combines the cytotoxic effect of Ad-TK with the immune stimulation induced by hsFlt3L leads to brain tumor regression and immunological memory in several intracranial rodent tumor models [8], [10], [32]. This evidence concerns the gene TKT and brain neoplasm.